Strive Health

1.1 Identity, Mission, and Care Model

Strive Health is a Denver-based company founded in 2018 to re-architect kidney care around earlier intervention, coordinated multidisciplinary support, and risk-bearing economics rather than the legacy system’s focus on late-stage dialysis. Authoritative company materials name Chris Riopelle and Will Stokes as co-founders, anchor the mission in the phrase "Redefining care. Elevating life," and repeatedly frame the business as a national leader in value-based kidney care. The core thesis is that kidney disease is too often detected late, managed in fragmented silos, and paid for through incentives that reward downstream intensity instead of upstream prevention. Riopelle’s personal origin story — seeing a close friend nearly reach kidney failure — appears consistently across Strive’s media kit, anniversary post, and independent local coverage, giving the founding narrative more credibility than a generic mission statement. The business model described across the homepage, media kit, and product pages has three tightly coupled elements. First, Strive deploys high-touch Kidney Heroes teams led by nurse practitioners and supported by nurses, social workers, dietitians, case managers, and care coordinators. Second, it embeds with local nephrologists, PCPs, health systems, and payors rather than replacing them. Third, it uses CareMultiplier, a kidney-specific machine-learning and predictive-analytics platform, to identify high-risk patients, surface care gaps, and prompt earlier interventions. Management presents the offering as a full-service solution spanning commercial plans, Medicare Advantage, traditional Medicare, health systems, physician groups, and CMS-linked programs. That is strategically important because it means Strive is not a single-contract point solution; it is trying to own the operating layer around value-based kidney care. The company’s positioning claims are strong but not entirely neutral. Strive calls itself the nation’s leader in value-based kidney care, and its materials cite 145,000-plus patients, 6,500-plus provider partners, and nearly $5 billion of medical spend under management. Those scale claims are corroborated across multiple 2024-2026 official releases and independent trade coverage. The stronger analytical takeaway is that Strive appears to have crossed from pilot-stage kidney-navigation vendor into a national specialty-care platform with meaningful operating reach, though public disclosures still emphasize operational metrics rather than revenue or profitability.[CO001, CO002, CO003, CO004, CO005, CO007]

1.2 Founders, Leadership Bench, and Governance Signals

Founder-market fit is one of the clearer strengths in Strive’s profile. Chris Riopelle did not enter kidney care from generic SaaS or payer-ops backgrounds; company materials say he spent a decade at Gambro and DaVita, ultimately leading a roughly $1 billion division before later serving as COO of LaVie Care Centers and CEO of NorthStar Anesthesia. That mix matters because Strive’s problem set sits at the intersection of nephrology operations, risk-bearing care delivery, post-acute complexity, and provider-network execution. The public origin story also shows why the product posture emphasizes patient navigation and earlier action rather than purely actuarial risk scoring. Will Stokes remains listed as co-founder and advisor, suggesting the founding bench persists even as the operating structure professionalizes. Strive’s leadership roster now looks much more like a scaled operating company than a startup improvising around a charismatic founder. The current public team includes Paul Marchetti as President, Jen Browne as COO, Orin McIntosh as CFO, Keith Bellovich as Chief Nephrologist, Tom Hawkes as CTO, Michele Paige as Chief Growth Officer, Sumair Akhtar as Chief Clinical Officer, Jon Kweller as General Counsel, Dave Thornton as Chief People Officer, and Amit Trivedi as Chief Actuary. The April 2025 executive-team expansion is especially notable because Marchetti arrived from CarelonRx and other large managed-care and provider-network settings, while Browne’s background spans quality, risk adjustment, disease management, and Optum-scale population health. That suggests Strive is consciously adding leaders who understand both specialty-care delivery and payer-style operating systems. Governance remains only partially transparent because Strive is private and does not publish a full board roster on the pages reviewed. Still, several signals are visible. Riopelle has accumulated regional and national recognition, including Denver Business Journal and EY honors, and Fierce Healthcare reported that NANI made an equity investment alongside venture backers in 2021, which implies strategic partner alignment beyond standard customer contracting. The main diligence caveat is that public sources reveal a strong executive bench but not enough about board independence, committee structure, or founder voting control to assess governance rigor with confidence.[CO002, CO005, CO006, CO008, CO009, CO010]

1.3 Funding History, Capital Base, and Strategic Stakeholders

Strive’s funding trajectory shows a company that moved from growth capital into true scale capital. The public record is strongest from 2021 onward: a $140 million Series B led by CapitalG in March 2021, a $166 million Series C led by NEA in May 2023, and a September 2025 Series D consisting of $300 million in equity plus $250 million in debt. Independent coverage by Fierce Healthcare, MedCity News, MobiHealthNews, Yahoo Finance, and HLTH aligns with the company’s own announcement that the Series D valued Strive at approximately $1.8 billion. The investor syndicate is also telling. NEA remained the lead equity sponsor, while CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint, BlackRock affiliates, and Hercules Capital all participated in the 2025 capital stack. This is a blend of venture, strategic healthcare, technology, asset-management, and specialty credit capital — a useful sign that Strive is being underwritten as both a care-delivery platform and an increasingly data-rich healthcare-infrastructure asset. The disclosed funding trail implies substantial cumulative capital. Because Strive said total funding stood at $223.5 million after the Series B, and later disclosed the Series C and D amounts, public materials support a minimum lifetime capital figure of roughly $939.5 million, including debt, and at least $689.5 million of equity. That is important for two reasons. First, it gives Strive a much larger capital cushion than many narrow digital-health companies. Second, it confirms the business has required significant financing to build national provider integration, care teams, analytics infrastructure, and multi-line contracting capabilities. Stakeholder depth extends beyond investors. Humana expanded a multi-state Medicare Advantage relationship in 2024, SSM formed a joint venture back in 2020, and CKCC-related nephrology relationships made Strive the largest non-dialysis participant at launch in 2022. The cumulative picture is of a company that has been able to convert funding momentum into institutional trust from both capital providers and strategic operating partners. The open question is whether that trust also translates into durable unit economics, because the public dataset highlights medical spend and clinical outcomes far more than recognized revenue or profitability.[CO014, CO019, CO020, CO021, CO022, CO023]

1.4 Milestones, Scale Signals, and Public Diligence Caveats

From a diligence perspective, Strive’s milestones read like a steady progression from regional kidney-care redesign to national platform status. The founding narrative starts in 2015 with Riopelle’s exposure to a friend’s kidney emergency, converts into company formation in 2018, and then becomes institutional through the 2020 SSM joint venture, the 2021 Series B, the 2022 CKCC expansion, the 2023 Series C, and the 2024 expansion to all 50 states. By early 2026, the media kit describes a company with 770-plus employees, 145,000-plus people served, more than 6,500 providers, and nearly $5 billion of managed medical spend. It also claims strong outcomes — 20% lower total kidney-care cost, 41% fewer hospitalizations, higher optimal dialysis starts, higher home dialysis adoption, and 94% patient satisfaction. Those are the metrics most central to Strive’s sales narrative and valuation support. There are two important caveats. First, public financial transparency remains thin. Even after a landmark Series D, the company’s public materials still do not disclose audited GAAP revenue, profitability, gross margin, or cash burn. Investors therefore appear to be underwriting Strive primarily on growth, operating scale, strategic relevance, and outcome claims rather than on fully transparent financial statements. Second, the external policy environment has turned less forgiving. Avalere and Jones Day both describe 2025 CMS changes to the Kidney Care Choices model as responses to provider attrition, tighter economics, and roughly $304 million of net losses in the model. Because Strive has built real scale in CMS-aligned and nephrology-linked value-based care, those changes are not abstract sector noise; they are a direct operating headwind if benchmark discounts, bonuses, or reimbursement mechanics continue to tighten. Overall, the company-overview evidence supports a positive but qualified conclusion. Strive has genuine national reach, unusually strong founder-market fit, blue-chip backers, and a differentiated kidney-care operating model. But it is still a private, capital-intensive company operating inside a policy-sensitive market where public evidence on profitability and governance remains incomplete.[CO015, CO016, CO017, CO018, CO027, CO028]

1.5 Exhibits

2.1 Market boundary, included spend, and substitutes

Value-based kidney care is not the entire renal market and it is not synonymous with dialysis reimbursement. The defensible boundary for Strive includes four connected layers: upstream CKD identification and risk stratification; high-touch care coordination that sits alongside nephrologists and PCPs; risk-bearing nephrology operations inside CMS or payer contracts; and downstream dialysis-transition, home-dialysis, and transplant navigation. CMS describes the KCC/CKCC structure as a coordinated model for Medicare fee-for-service patients with stage 4-5 CKD, ESRD, or transplant status, while Strive's own partner pages and media kit show the commercial market extending that same operating model to Medicare Advantage, Medicaid, commercial plans, nephrology groups, health systems, and physician partners. That framing matters because it keeps the chapter focused on operating and contracting layers where Strive can earn value, not on the entire dialysis facility revenue pool or every generic chronic-care software category. The clearest public evidence for why the boundary matters comes from the split between disease burden and paid-market structure. Official sources put the adult CKD population in the mid-30 millions, yet the treated ESKD population is only a small fraction of that total and CKCC/KCC aligned beneficiaries are smaller still. Public Medicare spending lenses also vary sharply by what is included: older-adult CKD claims, ESKD-specific spend, dialysis facility payments, or broader kidney-disease totals. Company sources then go further, using unmanaged-spend figures above $400 billion that are directionally useful but not directly comparable to Medicare-only baselines. Treating all of those numbers as the same TAM would overstate certainty. The legacy substitutes are likewise broader than a simple list of startup competitors. Status-quo kidney care is still anchored in fragmented fee-for-service nephrology follow-up, dialysis-provider operating models, and general payer case-management programs. Specialty kidney-care platforms only create incremental economic value if they coordinate across those silos better than the default stack. Strive's nephrology and payor materials repeatedly position the company as the connective layer rather than as a dialysis owner or a thin analytics widget, which supports defining the market around integrated, value-based kidney operations rather than around undifferentiated renal reimbursement.[CM006, CM007, CM008, CM010, CM011, CM012]

2.2 TAM, SAM, and SOM through prevalence and spend lenses

The broadest sizing lens is patient prevalence. CDC's March 2026 report estimates 37 million U.S. adults, or 14% of adults, have CKD, while NIDDK summarizes the population at 35.5 million. Those are close enough to bracket the true population need, and both sources also show that CKD is deeply underdiagnosed. That supports a large upstream opportunity for identification, education, and care coordination, but it does not automatically translate into vendor revenue because many patients will never enter a risk-bearing kidney contract. The more economically relevant sub-layers are much smaller: NIDDK reports a treated ESKD population a little above 808,000, CMS's own value-based model data show about 257,000 aligned KCC beneficiaries by PY2025, and Strive's disclosed current served base is 145,000-plus people. The spend lens is equally important and more contradictory. Official public baselines show nearly $77 billion of Medicare spending for beneficiaries 66+ with CKD excluding ESKD in 2021, plus another $52.3 billion of Medicare-related ESKD spend. CMS separately expects to pay about $6 billion to 7,600 ESRD facilities under the CY2026 ESRD PPS, and the official CKCC infographic still describes ESKD as over 7% of Medicare spending despite representing only 1% of beneficiaries. Strive's 2026 media kit then cites approximately $156.7 billion, or one in four Medicare dollars, spent on people with kidney disease, and pairs that with a much larger $456 billion unmanaged-spend estimate. The right interpretation is not that one source is obviously wrong; it is that each source draws a different market boundary. For SOM, public evidence supports only a constrained lens. Strive's 145,000-plus served patients and roughly $5 billion of spend under management show real operating scale, but they still imply a served share well below 1% of the national CKD population. That gap is why the current market looks simultaneously large and early: the disease burden is massive, yet the actual contracted and coordinated population remains narrow relative to total prevalence. The practical takeaway is that any Strive TAM story should present multiple lenses at once and preserve the boundary differences instead of collapsing them into one oversized headline number.[CM001, CM003, CM004, CM005, CM006, CM007]

2.3 Buyer and channel segmentation

The buyer map is multi-sided because value-based kidney care is sold through contracts, not just software seats. CMS and its participating Kidney Contracting Entities are one buyer class: the KCE structure requires nephrologists or nephrology practices plus transplant providers, can optionally include dialysis facilities, and increasingly relies on integrated kidney care organizations for operations, education, and analytics. That makes nephrology groups both users and channel owners. Strive's nephrologist page explicitly leans into that structure by saying nephrologists are in the driver's seat of new value-based models, including CKCC and Medicare Advantage full-risk arrangements. Health plans form the second major buyer class. Strive's payor page is explicit that the offering targets commercial, Medicare Advantage, and Medicaid plans, and the 2024 Humana expansion announcement shows how that looks in practice: a multi-state agreement for most Humana Medicare Advantage HMO and PPO members with kidney disease, covering interdisciplinary care, dialysis-access planning, transplant coordination, medication management, and social services. The CKD Spotlight dashboard adds a useful market signal here because it is built from national multi-payer claims and segments CKD diagnosis and management by payer and geography, reinforcing that payers have enough data and enough spend concentration to treat kidney care as a distinct management category rather than as a generic case-management problem. Health systems and provider organizations are the third buyer/channel class, while integrated kidney care organizations sit across the stack as operating enablers. Strive's media kit says the company is a full-service solution for providers, health systems, payors, and patients, and Echo's CKCC launch announcement showed the same channel logic earlier: Strive working with 260 nephrology providers in 27 groups, while also courting commercial payers, health systems, and medical groups. The important market implication is that adoption does not move through one procurement path. Some contracts are payer-led, some are nephrology-led, and some rely on co-selling or operating partnerships between specialists and plans.[CM013, CM014, CM015, CM020, CM026, CM027]

2.4 Growth drivers, adoption constraints, and evidence gaps

The strongest demand drivers are upstream need and policy-backed care redesign. Public health sources still show a huge undiagnosed CKD population, while CMS's own KCC evaluation shows measurable clinical improvements when providers receive incentives to intervene earlier: higher home-dialysis use, more living donor transplants, more preemptive waitlisting, and better optimal ESRD starts. NKF's 2026 rule comments push in the same direction by advocating for home dialysis access, Kidney Disease Education, and Medical Nutrition Therapy. Strive's March 2026 resource center post adds a market-level narrative on top of that evidence, emphasizing early cardiometabolic intervention, SGLT2 adoption, and cross-specialty collaboration. Taken together, these sources support a market where upstream kidney management is becoming more clinically credible and more strategically important to payers and nephrologists. The main constraint is that policy support does not equal easy economics. KCC's own evaluation says the model did not significantly reduce total Part A/B payments and instead increased Medicare spending by $304.8 million, largely because of incentive payments. CMS and outside legal/policy summaries responded by tightening the model: KCF participation is sunset, graduated/professional/global CKCC tracks extend through 2027 but face additional benchmark discounts, transplant bonuses disappear in 2026, and CKD quarterly capitation is cut by half. Avalere's participant data show that the number of KCF practices and CKCC entities fell sharply even as aligned beneficiaries ticked up, with stakeholders pointing to downside risk and documentation burden. In other words, adoption drivers are real, but the public evidence does not yet show a frictionless or obviously high-margin market. A second structural constraint sits outside CMS: dialysis-provider concentration and MA economics. The PMC pricing study argues that MA enrollment after dialysis initiation became more relevant after the 21st Century Cures Act and could rise further, but it also finds that large dialysis organizations negotiated materially higher MA prices than FFS Medicare. That makes Medicare Advantage a double-edged sword for kidney-care vendors and plans alike: more beneficiaries can enter managed models, but medical-loss economics are harder when downstream dialysis prices stay elevated. Staffing shortages at smaller or rural clinics add another execution constraint. The unresolved diligence questions therefore sit less on whether kidney care matters and more on exactly how much of this spend a vendor like Strive can capture, at what margins, and through which buyer mix under tighter 2026-2027 reimbursement terms.[CM016, CM017, CM018, CM019, CM021, CM022]

3.1 Landscape shape: direct peers, incumbents, adjacencies, and substitutes

The kidney value-based care landscape is no longer a simple Strive-versus-one-vendor comparison. Independent market analysis says the field is still anchored by a concentrated dialysis base dominated by DaVita and Fresenius, while newer payment models and Medicare Advantage growth are pulling nephrology practices, payers, dialysis chains, and MSO-style partners into more risk-bearing relationships. In practice that creates at least four rival classes for Strive: direct specialty platforms such as Monogram, Somatus, Interwell, and Evergreen; incumbents such as DaVita Integrated Kidney Care and the Fresenius ecosystem; adjacent care-delivery channels such as Oak Street or home-health partners; and the status quo of payer case-management or nephrology-practice internal build. Strive is not out of place in that set, but neither is it alone. Stout’s market map places Strive among multiple converging entrants rather than in a category of one, and several competitors publicly describe almost the same buyer promise: earlier intervention, multidisciplinary care, fewer hospitalizations, more home-dialysis uptake, more transplant readiness, and lower total cost of care. The real differentiation therefore shifts away from the generic marketing language and toward harder questions: which platform owns the payer relationship, which one controls nephrologist workflow, which one has physical care-delivery assets, and which one can actually implement analytics quickly enough to matter. Those are the lenses used for the rest of this chapter.[CP001, CP002, CP039, CP040, CP041, CP044]

3.2 Direct platform peers: Monogram, Somatus, Interwell, and Evergreen

Among the direct platforms, Monogram and Somatus look most like scaled payer-facing alternatives to Strive, but they reach that position differently. Monogram’s public pack is centered on in-home multispecialty care and health-plan partnerships. It disclosed a $375 million round in 2023, broad strategic backing from payer and investor stakeholders, and a footprint that at that time covered 34 states and nearly 4,000 cities. Humana and Aetna partnership materials reinforce that Monogram wins through plan relationships, home visits, and transplant-evaluation coordination, not through nephrologist ownership or a hard dialysis footprint. Somatus is the more openly scaled peer in the current public dataset. It now says it serves more than 500,000 patients across all 50 states and DC, manages more than $14 billion in healthcare costs, and contracts with more than 100 nephrology practices and 5,500 providers. Importantly, Somatus also disclosed stronger public home-dialysis and transplant outcomes than most peers, which matters because those are exactly the outcomes Strive uses in its own sales story. Interwell is different again. The 2022 merger combined Fresenius contracting infrastructure, a large nephrologist network, and Cricket’s analytics and engagement stack into one entity. That makes Interwell the clearest nephrologist-first platform peer, especially because later reporting shows continued payer expansion and Oak Street adjacency. Evergreen is smaller in public scale but strategically notable because it offers nephrology practices an operational on-ramp from chronic-care-management economics into broader value-based care, including new Phamily-enabled AI workflows.[CP007, CP008, CP010, CP011, CP012, CP013]

3.3 Incumbents and channel power: DaVita and Fresenius still own the hardest assets

The most serious strategic pressure on Strive does not come only from the direct platforms. It comes from incumbents that can combine value-based contracting with physical access, referral pathways, and durable provider relationships. DaVita’s public materials are unusually explicit here: it claims more than $5 billion in costs under management, more than 220,000 CKD and ESKD patients managed, 2,300-plus physician partnerships, 32,000-plus home-dialysis patients, and 120,000-plus transplants over twenty years. Even if those metrics are company-framed, they point to a competitive reality that software-first peers cannot easily replicate. Fresenius, even after contributing Fresenius Health Partners to Interwell, still matters because its ecosystem continues to emphasize home dialysis, transplant access, interoperability, and health-plan collaboration. Becker’s reporting on the Cigna relationship illustrates the underlying power: access to a national dialysis-center footprint and home options can be bundled into payer contracts in ways that make procurement and patient-routing easier for buyers. That same scale creates a second-order risk. Home Health Care News treated the DaVita-Elara move as evidence that kidney incumbents are pushing further into the home and also flagged renewed antitrust concerns. For Strive, the implication is straightforward: incumbent response is not hypothetical. Large operators can extend from dialysis into adjacent home-health and value-based partnerships while using existing patient touchpoints and provider economics to defend share.[CP026, CP027, CP028, CP029, CP030, CP031]

3.4 What actually differentiates Strive, and how durable is it?

On public evidence alone, Strive’s best wedge is not simple size. Somatus discloses the larger current managed-population number, Monogram has heavyweight payer investors and national in-home reach, Interwell owns the clearest nephrologist-governance story, and DaVita or Fresenius have the deepest physical and channel assets. Strive instead looks strongest where buyer breadth and implementation speed matter together. Its public materials show meaningful payer range, nephrologist support, and a kidney-specific AI platform that claims unusually fast partner onboarding. That combination can matter for plans or provider groups that want a kidney-specialty operating layer without taking on incumbent dialysis alignment. The durability question is less settled. Public pricing is mostly opaque across the peer set, so outside investors cannot see who has the best real economics. Several competitors also position themselves as extensions of nephrologists or home-based teams, which suggests that switching costs may be lower than headline marketing implies and that multi-homing may remain common. Finally, the current reimbursement scaffolding runs through 2026, while the more transplant-inclusive next generation is still proposed rather than locked. The net result is a market where Strive clearly belongs in the top competitive tier, but where moat claims should be framed as conditional on partner retention, contract economics, and the next policy cycle rather than as already settled fact.[CP001, CP003, CP004, CP005, CP006, CP016]

3.5 Exhibits

4.1 Revenue model and monetization: risk-bearing kidney contracts, not a software seat

Public evidence points to Strive making money by sitting inside value-based kidney contracts rather than by selling a standalone software seat. Strive's payor page says the company is accountable for quality outcomes and financial performance for members with chronic kidney disease and end-stage kidney disease across commercial, Medicare Advantage, and Medicaid populations. Its nephrologist page says CKCC and Medicare Advantage full-risk contracts are core use cases, while the NANI partnership announcement says the parties will jointly pursue and manage global risk payment models. Humana's 2024 announcement adds a concrete payer-channel example: a multi-state Medicare Advantage agreement for kidney-disease members. Taken together, those sources support a monetization model built from care-management operations, embedded analytics, and upside/downside performance economics. The same source pack also shows why medical spend under management is not revenue. Public Strive-related disclosures moved from roughly $600 million of medical spend in the 2022 CKCC launch context, to more than $2.5 billion in a 2023 Business Wire announcement, to nearly $5 billion in 2025-2026 company and news coverage. Those numbers are meaningful because they signal budget responsibility and the breadth of populations under management. They are not the same as recognized revenue, however, because the spend denominator includes downstream medical claims paid across attributed populations rather than dollars retained by Strive. Without disclosed take rates, capitation PMPMs, admin-service fees, or shared-savings splits, investors cannot convert spend under management into top-line revenue with confidence. That leaves pricing transparency thin. None of the reviewed official, partner, or trade sources disclosed list pricing, realized PMPMs, or the exact allocation of upside and downside by channel. The defensible conclusion is that Strive monetizes through payer and provider contracts that bundle clinical operations, technology, and financial accountability, while the exact revenue-recognition mechanics remain private.[CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Unit economics and what the public record still cannot prove

Public unit-economics visibility is materially weaker than public operating-scale visibility. Strive's media kit and Series D materials give a credible scale snapshot: more than 145,000 people served, more than 6,500 provider partners, nearly $5 billion of annual medical spend under management, and more than 770 employees by early 2026. Those are useful underwriting proxies because they show Strive is not a tiny pilot vendor. They still do not answer the core finance questions that matter most for venture underwriting: recognized revenue, gross margin, EBITDA, free cash flow, monthly burn, runway, CAC, payback, renewal rates, or net revenue retention. The public model description suggests why. Strive repeatedly describes itself as an extension of the provider office, with nurse-practitioner-led and multidisciplinary care teams wrapped around data and workflow tools. The provider-integration piece specifically says Strive serves as an extension of a provider's office, and the nephrologist materials emphasize support for CKCC and full-risk contracts. That points to a service-heavy cost base in which clinician payroll, care coordination, implementation, provider onboarding, and analytics development all matter. It also implies margins are likely determined less by classic software hosting efficiency and more by care-team productivity, contract design, and how quickly technology can reduce avoidable utilization. Outcome evidence may strengthen revenue quality without revealing unit economics. Strive's 2025 resource-center summary of peer-reviewed research says stage 3b CKD patients in its program saw a 77.2% reduction in CKD progression rate and stage 4 patients saw a 65.2% reduction. That type of evidence can make payer renewals and provider alignment more plausible. But public readers still do not get the contract math behind those outcomes. The correct stance is therefore to use public scale and outcome disclosures as quality signals while treating all margin, take-rate, and profitability conclusions as open diligence items rather than as solved facts.[CI008, CI025, CI026, CI028, CI029, CI030]

4.3 Capital history, investor mix, and capital adequacy

The funding chronology itself already appears in Company Overview; the financial question here is what the sequence implies about capital needs. Public sources support a step-up from a $140 million Series B in 2021, to a $166 million Series C in 2023, to a $550 million Series D in 2025 made up of $300 million of equity and $250 million of debt. Using only disclosed round amounts, that yields a minimum lifetime capital figure of about $939.5 million including debt and at least $689.5 million of equity. The latest round also broadened the capital stack. Equity investors included NEA, CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint, and BlackRock-managed funds or accounts, while Hercules Capital led the debt tranche. That mix matters for two reasons. First, it suggests outside investors view Strive as more than a niche care-navigation startup; the company is being financed like a scaled healthcare-operations platform with software leverage and strategic channel importance. Second, the debt component means headline capital raised overstates equity cushion if an analyst treats the full $550 million as permanent risk capital. About 45.5% of the latest gross proceeds came from debt rather than equity. Public sources say the proceeds will fund AI investment, multi-specialty expansion, and deeper payer-provider partnerships, but they do not disclose the borrowing rate, maturity, amortization, or covenants attached to the Hercules facility. Capital adequacy is therefore directionally positive but not fully underwritable. Strive has clearly raised enough to keep scaling nationally, and the lender context is credible: a Hercules SEC-filed earnings release showed record Q1 2026 commitments, $706.4 million of quarterly fundings, and over $1.0 billion of available liquidity. Even so, cash on hand, monthly burn, runway, and the internal milestones for the next financing are not public. The business also looks more working-capital intensive than fixed-asset intensive: there is strong evidence of labor-heavy care operations and implementation work, but no comparable evidence of dialysis-clinic ownership or other hard-asset capex that would make it look like DaVita or Fresenius.[CI014, CI015, CI016, CI017, CI018, CI019]

4.4 External economics and the right public-underwriting stance

The external economics around kidney value-based care put real limits on how bullish a public-only financial read can be. CMS's second KCC evaluation report says the model improved several quality markers but still increased Medicare spending by $304.8 million, mostly because of incentive payments. CMS then tightened the model for performance year 2026: quarterly CKD capitation is cut by 50%, the Kidney Transplant Bonus is eliminated, and the Kidney Care First track ends at the close of 2025 while CKCC continues through 2027 under tougher terms. Avalere adds another financial warning sign, reporting that KCF practices fell from 30 to 15 and CKCC entities from 100 to 75 even as aligned beneficiaries rose to about 257,000 by PY2025. Fierce's contemporaneous coverage framed those changes explicitly as an effort to improve model sustainability. Downstream dialysis economics complicate the picture further. The PMC study on Medicare Advantage dialysis pricing found that MA plans paid 27% more than fee-for-service Medicare on average and that larger dialysis chains commanded higher markups. For Strive, that matters because payer savings pools can get squeezed if upstream coordination lowers utilization but downstream dialysis prices remain elevated. In other words, Strive does not control all of the economics inside the kidney cost stack it is trying to manage. The practical underwriting implication is that public evidence supports scenario ranges, not precise models. Investors can see substantial capital raised, meaningful operating scale, and nontrivial clinical-outcome support. They cannot see audited revenue, profitability, gross margin, cash burn, runway, debt terms, realized pricing, take rates, retention, or cohort-level contribution margins. The financial verdict is therefore favorable on strategic relevance and access to capital, but still constrained by missing private numbers and a reimbursement environment that has become less forgiving in 2026.[CI037, CI038, CI039, CI040, CI041, CI042]

4.5 Exhibits

5.1 Public product modules and the kidney-care workflow they are built to serve

Strive's product surface is narrower than a broad digital-health suite but broader than a single analytics tool. The official solutions pages consistently bundle four named components: Population Health, Kidney Heroes, CareMultiplier, and Strive Care Partners. Taken together, they define a workflow that starts with identifying kidney-risk patients earlier, moves through high-touch clinical outreach, and then supports nephrologists, health systems, and payors inside value-based arrangements. The public pages do not market a software seat in isolation; instead they present software, staffing, and contracting support as one coordinated delivery model. That workflow emphasis is visible in the user jobs each module covers. Population Health focuses on proactive patient identification, education, and progression management before kidneys fail. Kidney Heroes are the operational layer: nurse-practitioner-led, multispecialty teams that act as care extenders for nephrologists while coordinating with PCPs and other specialists. Strive Care Partners is the nephrologist-facing risk-enablement wrapper for CKCC and Medicare Advantage full-risk models. CareMultiplier sits behind those services as the kidney-specific data and predictive layer that feeds interventions to care teams. Humana's multi-state announcement adds concrete workflow detail by naming medication management, dialysis access planning, transplant coordination, and social services as part of the delivered service. The practical implication is that Strive sells into payer/provider workflows, not around them. Product maturity therefore depends less on flashy standalone features and more on whether these modules actually reinforce each other at the point of care. Public evidence suggests they do, especially for preventative kidney management and nephrology support. The trade-off is that outside readers get a strong care-model description but much less transparent module-level documentation than they would expect from enterprise software sold as a separate platform.[CE001, CE002, CE003, CE004, CE009, CE010]

5.2 Technology and operating architecture: data aggregation, risk scoring, workflow integration

The most specific public technical description comes from Strive's CareMultiplier materials and provider-integration content. Those sources say CareMultiplier aggregates and standardizes data from many or even hundreds of sources, runs kidney-specific predictive models, and feeds actionable outputs into a proprietary care-management workflow suite and EMR-connected processes. The model outputs named publicly include dialysis-crash risk, admission and readmission risk, disease-progression risk, and identification of undiagnosed kidney disease. Strive also says the platform can trigger around-the-clock alerts and population-level dashboards so clinicians can act before expensive events occur. The architecture that emerges from those sources is not an API-first developer product; it is a human-in-the-loop operating stack. Data comes in from partner environments, CareMultiplier standardizes and scores it, provider-integration teams connect the outputs to EMR and workflow processes, and Kidney Heroes or partner clinicians execute interventions. The integration playbook is unusually explicit on process even if it is light on software internals: proactive provider outreach, in-person practice visits, standardized communication channels, role setting, interoperability goals, and compliant EMR integration are all documented publicly. Strive also makes aggressive deployment claims, including integrating partner data in under two weeks and standing up a new partner model in 90 days. That combination of analytics plus workflow design is a real differentiator, but it also reveals the chapter's main technical constraint. Strive discloses outcomes and operating claims, not deep system documentation. Public materials do not expose APIs, data schemas, model cards, uptime commitments, or incident-history surfaces. As a result, the operating architecture is intelligible at the business-process level and still partially opaque at the software-engineering level.[CE005, CE006, CE007, CE008, CE013, CE014]

5.3 Trust, quality, and clinical validation: strong evidence, but some of it is aging

Trust and quality claims are a meaningful part of Strive's product story because the company sits inside regulated care workflows and handles sensitive patient data. Public company materials repeatedly cite two programmatic controls: NCQA accreditation for case management and population health, and HITRUST certification for CareMultiplier. The supporting source set is reasonably detailed on what those attestations mean. The NCQA announcement explains how Strive separates higher-intensity case management from broader population-health support and ties both programs to continuity of care, patient education, and planned modality selection. The HITRUST announcement links CareMultiplier to a formal security-control framework and explicitly references privacy, compliance, and information-risk management. Clinical-validation evidence is also stronger than a typical private care-enablement company's public record. Strive's 2025 research summary and the AJMC article report slower eGFR decline for enrolled stage 3b and stage 4 CKD patients. The Duke HV-EQ case example adds more structured external packaging around downstream outcomes, including optimal dialysis starts, home-modality adoption, total-cost-of-care reduction, and hospitalization improvement. The media kit layers on company-reported engagement and satisfaction metrics. Taken together, these sources support the claim that Strive has a validated care model rather than only a marketing narrative. The caveat is freshness and externality. The most detailed NCQA and HITRUST explanations recovered in this run are older company-authored posts from 2021-2022, while 2025-2026 materials mostly restate the claims rather than linking to current registries or scoped attestations. That does not mean the controls are false. It means public procurement-grade evidence is thinner than the headline claims suggest, so diligence should verify current certification scope and renewals directly.[CE017, CE018, CE019, CE021, CE022, CE023]

5.4 Roadmap, maturity, and unresolved technical opacity

Public maturity signals are substantial. By early 2026 Strive claimed 145,000-plus patients, 6,500-plus provider partners, nationwide reach, and 770-plus employees, which is too much operating scale to dismiss as a pilot story. The September 2025 Series D announcement also tied fresh capital directly to AI-driven tools, deeper payer-provider partnerships, and multi-specialty expansion. The March 2026 Strive On Live recap sharpens that roadmap by discussing AI-enabled population identification, compliance concerns, and cardiometabolic collaboration. Outside the product pages, hiring signals reinforce the same direction: public job postings point to AI engineering, data infrastructure, and engineering leadership needs rather than a frozen platform. Those are all signs of a product stack that is still being actively built and broadened. They also suggest Strive is trying to extend from kidney-only management toward a more multi-specialty, whole-person care architecture without abandoning nephrology as the center of gravity. That is strategically sensible because CKD outcomes are tightly linked to diabetes, hypertension, and cardiovascular disease, and Strive's workflow pages already emphasize coordination across specialties. The unresolved issue is that maturity is easier to see in operations than in documentation. Developer-signal exists, but it is mostly indirect through hiring pages, not through a public documentation surface, release notes, or a visible developer ecosystem. The public record therefore supports a nuanced conclusion: Strive looks mature as a deployed care-and-tech platform, but still relatively opaque as a software platform. That does not invalidate the product thesis; it simply means the technical moat and reliability story should be underwritten with private diligence rather than public marketing alone.[CE016, CE020, CE024, CE025, CE026, CE029]

5.5 Exhibits

6.1 Customer segments and public scale

Strive's customer base is best understood through who bears risk and who owns workflow. The company is not selling a narrow point solution to one buyer. Its public surfaces split the market into payors, health systems, and nephrologists, while the patient-facing layer sits underneath as the served population rather than the paying customer. That framing matters because the evidence recovered in this run consistently shows Strive entering through value-based kidney-care economics, then embedding care teams and workflow support around local clinicians. In other words, the payer may fund the model, the provider may operationalize it, and the member or patient is the end user, but the commercial relationship is still with institutional customers. The public scale signals are real but easy to misread. Strive disclosed more than 121,000 served patients, more than 6,500 provider partners, and all-50-state reach by September 2024. Those numbers support national deployment reach, yet they are not the same thing as the number of paying customers. The source set never converts patient volume into a distinct logo count, nor does it break revenue by channel. That leaves a clear public takeaway: Strive has meaningful customer breadth across payer and provider channels, but investors still need private diligence to understand how many active accounts actually sit underneath the served-population numbers.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Named customer proof and freshness

Named proof is stronger here than in many private-company customer chapters. Humana is the cleanest payer proof because three public sources line up on the same 2024 expansion, the five-state footprint, the 2020 relationship starting point, and the specific care services delivered. Regence and Medical Mutual add additional health-plan confirmation with disclosed member counts and clear deployment scopes. Zing is important not because it is the largest named account in public materials, but because the 2025 release explicitly calls the move an expansion of an existing partnership, which is rare public evidence of repeat business. On the provider side, SSM Health, Bon Secours Mercy Health, NANI, and Oak Street show that Strive is not limited to payer contracting. SSM and Bon Secours show health-system collaboration; NANI shows deep nephrology workflow integration and global-risk governance; Oak Street shows a Medicare-focused primary-care channel for advanced-kidney patients. The company-about page and nephrologist page add testimonial proof from additional groups such as Michigan Kidney Consultants and Midwest Nephrology Associates. The caveat is freshness and depth. Some logos remain publicly visible in 2026, but many deployments are still described through one announcement, one quote, or one case-study style narrative rather than through ongoing current-operating disclosures.[CU007, CU008, CU009, CU010, CU011, CU012]

6.3 Deployment path and expansion motion

The public record suggests a repeatable deployment pattern. First, Strive signs a value-based arrangement with either a payer, health system, or nephrology group. Second, it integrates data and workflow around local clinicians, usually through Kidney Heroes teams, analytics, and care-management support. Third, it uses that embedded model to expand into additional states, lines of business, or adjacent channels. Humana is the clearest example because the 2024 agreement explicitly builds on a 2020 starting relationship. Zing is the clearest freshness signal because the 2025 announcement is framed as an expansion of an existing relationship across six states. Medical Mutual broadens the playbook by spanning Medicare Advantage, individual, and commercial group lines in one state rather than only one MA population. Provider-side deployments follow the same logic. NANI and the broader CKCC footprint show Strive integrating into nephrology workflows and risk governance; Oak Street shows a primary-care referral and support channel; and Bon Secours plus SSM show system-level adoption. That combination implies Strive's expansion path is less about pure software-seat growth and more about contracting plus workflow penetration. The chapter can therefore underwrite a credible land-and-expand motion. What it cannot underwrite from public evidence alone is whether these expansions materially improve retention, wallet share, or unit economics over time.[CU012, CU013, CU015, CU017, CU018, CU020]

6.4 Durability, concentration, and disclosure gaps

Durability is where the public record thins out sharply. The strongest public retention signal is not a disclosed NRR or renewal table; it is the fact that Humana and Zing both announced expansions of existing relationships. That is useful, but it is still anecdotal relative to what an investor would normally want. None of the reviewed public materials disclose NRR, GRR, logo churn, renewal cadence, average contract length, top-customer revenue share, or payer mix by revenue. Even customer count is under-disclosed because the company prefers to publish served-patient and provider-partner totals rather than distinct active-account totals. Satisfaction evidence has the same shape. The company-reported 94% patient satisfaction figure is directionally positive, but the methodology is not public and no independent benchmark surfaced in this run. The adverse search likewise found only a low-confidence anecdotal thread about confusing outreach rather than a formal complaint pattern or a documented failed deployment. The right conclusion is therefore balanced rather than bearish. Public evidence is strong enough to prove real customer adoption across multiple channels, yet it is still too thin to clear the hardest underwriting questions on retention, concentration, and renewal economics. Those remain explicit diligence asks, not hidden assumptions.[CU029, CU030, CU031, CU032, CU033, CU038]

6.5 Exhibits

7.1 Reimbursement reset and regulatory risk

The biggest risk to the Strive thesis is not whether kidney value-based care exists as a concept. It is whether the economics of participating in that market still work after the 2026 Kidney Care Choices reset. CMS, legal alerts, and Avalere all point in the same direction: Kidney Care First ends early, CKCC survives but under harsher benchmark discounts, the transplant bonus disappears, and CKD capitation is cut in half. The second CMS evaluation makes the policy motive explicit by showing that quality improved in several areas while Medicare spending still rose by $304.8 million, mostly because of incentive payments. That combination creates real policy-churn risk for every operator whose story depends on kidney-risk contracts staying generous enough to fund intensive care management. Strive is especially exposed because its public positioning repeatedly ties the business to risk-bearing arrangements with Medicare, Medicare Advantage plans, and nephrology groups operating in CKCC-like environments. The company can plausibly absorb policy tightening if it is diversified into commercial and MA economics that still reward outcomes, but public sources do not quantify that mix. What investors can say from public evidence is narrower: Strive operates in the part of kidney care where CMS is explicitly trying to squeeze sustainability, and its most visible public payer and provider relationships are exactly the kinds of channels that feel policy resets quickly. The mitigation is not that policy is stable; it is that CMS chose to keep CKCC running through 2027 instead of shutting the model entirely, which leaves room for scaled operators to prove they can still win under tighter terms.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Operational, quality, and trust risk

Strive is not a light-touch software vendor, so the main operating risk is execution density. The company’s own materials say its model works by embedding local integration, care coordination, interoperability, and a nurse-practitioner-led care team into nephrology and payer workflows. That can be a strength when the organization is disciplined, but it also means quality and margin are vulnerable to staffing lag, inconsistent provider adoption, and weak handoffs between analytics and the actual care team. Public outcome claims and peer-reviewed signals are directionally strong, yet they do not erase the fact that Strive has to keep reproducing those results while scaling nationally and while reimbursement conditions get tougher. The security and trust layer is similar. Publicly, Strive can point to HITRUST certification, NCQA accreditations, and a privacy policy that outlines collection, service-provider use, and transfer rights. Regulators, however, care about the harder operating details beneath those labels. HHS says business associates handling ePHI need appropriate administrative, physical, and technical safeguards, a foundational risk analysis, and timely breach notification. HIPAA Journal’s 2026 enforcement summary shows OCR is still leaning into risk-analysis and risk-management failures. The underwriting implication is balanced rather than alarmist: this run did not surface a confirmed Strive-specific OCR action or breach disclosure, but it also did not surface the kind of independent control evidence that would let an investor underwrite cyber and privacy risk as solved.[CR013, CR014, CR015, CR016, CR017, CR018]

7.3 Partner, capital, and people risk

Public evidence says Strive is now large enough that partner dependence matters more than pure product novelty. The company’s disclosed reference set clusters around a handful of visible payer and provider channels: Humana, NANI, Oak Street, Aetna, Blues plans, and a broader provider base that Strive says exceeds 6,500 organizations or clinicians. That is enough to prove real market penetration, but not enough to prove concentration is benign. Public materials do not show the revenue weight of any one payer, nephrology group, or health-system relationship. At the same time, Stout and the Medicare Advantage dialysis-pricing study show that incumbents such as DaVita and Fresenius still sit inside a concentrated kidney ecosystem where downstream economics can remain stubborn even when upstream coordination improves. Capital and people risk compound that dependence. Strive’s 2025 round mixed $300 million of equity with $250 million of Hercules-led debt, and management says the money is meant to deepen partnerships, expand specialties, and accelerate AI investment. That is bullish only if the organization can convert spending into repeatable outcomes and renewals faster than policy and channel pressure compress margins. The company also appears to be scaling a relatively compact executive bench over a 700-plus-person workforce. Public sources show material hiring across clinical, technical, data, operations, and strategy roles, plus leadership additions at the president and COO levels. That is exactly the kind of profile that can create great operating leverage or painful inconsistency depending on onboarding discipline, retention, and how much the company still depends on a few senior leaders to keep the machine aligned.[CR011, CR012, CR028, CR029, CR030, CR031]

7.4 Mitigations, monitoring, and kill criteria

The right way to underwrite Strive from public evidence is to treat mitigation as necessary but not yet sufficient. There are real mitigants in the source pack: CKCC survives through 2027 instead of ending immediately; Strive has credible scale, public payer and provider proof, outcome evidence, HITRUST and NCQA badges, and enough capital to keep investing. But each mitigation is paired with an unresolved diligence burden. Survival of CKCC is not the same as attractive unit economics. Public outcomes are not the same as independent, contract-level renewal proof. Certifications are not the same as a current operational control package. A large debt-backed raise is not the same as covenant-free flexibility. That framing leads to clear kill criteria. If management cannot quantify channel exposure to the 2026 reimbursement reset, the thesis should weaken quickly because policy risk is no longer abstract. If independent cohorts fail to replicate hospitalization, progression, or cost claims under current economics, the renewal story breaks. If a material privacy or security incident forces notices or triggers regulator scrutiny, procurement and trust can deteriorate far faster than headline growth suggests. And if leadership or workforce scaling slips while debt remains opaque, investors should assume execution risk is rising, not falling. The chapter therefore ends with a qualified view: Strive still looks strategically relevant, but the residual risk stack is high enough that the investment case depends on management proving concentration, post-reset resilience, and control depth in diligence rather than in marketing materials.[CR007, CR041, CR042, CR043, CR044, CR045]

7.5 Exhibits

8.1 Priceability starts with disclosed economics, and those are still missing

The headline round is easy to repeat and hard to underwrite. Strive's official September 2025 financing announcement and contemporaneous coverage support a $550 million Series D made up of $300 million of equity and $250 million of debt, with outside coverage placing the round at roughly a $1.8 billion valuation. Public materials also support that this is not a tiny vendor: Strive says it serves more than 145,000 people with kidney disease, works with more than 6,500 provider partners, operates across all 50 states, and manages nearly $5 billion of annual medical spend. Those are meaningful relevance signals. They are not enough to prove valuation. The same public record still does not disclose recognized revenue, gross margin, EBITDA, realized PMPMs, shared-savings splits, or the debt terms and preference stack that determine what the headline valuation means for common-equity upside. That distinction matters because medical spend under management and patient counts are not transferable valuation denominators. Spend under management is a claims pool, not Strive's retained top line. Patient counts are also poor stand-ins for value unless investors can see payer mix, take rate, contract duration, nurse-practitioner intensity, and whether economics come from shared savings, admin fees, or some hybrid structure. Public evidence therefore says two things at once. First, Strive clearly matters in kidney value-based care. Second, the company is not publicly disclosed enough to support a precise EV-revenue or EV-EBITDA judgment. The right analytic posture is to use the current mark as a bracketed scenario input rather than as a proven fair price.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Direct comps bracket plausibility, but not a point estimate

The comparable set is directionally useful and mechanically imperfect. Oak Street is the strongest precedent because it shows what a scaled, capitated, value-based care asset can fetch when revenue is disclosed and a strategic buyer can diligence the model deeply. CVS paid about $10.6 billion enterprise value for Oak Street after Oak Street had already reported $2.16 billion of 2022 revenue and $2.13 billion of capitated revenue. That is far more disclosure than Strive provides today, which is exactly why Oak Street is informative but not directly portable. On the public side, Alignment, DaVita, and Fresenius show another important reality: large, disclosed healthcare operators often trade around modest sales or revenue-value relationships even when strategically relevant. Alignment's market cap and low-1x sales signal, DaVita's roughly revenue-sized market cap despite profitable integrated kidney care, and Fresenius's large revenue base relative to market value all argue against assuming that a private kidney platform automatically deserves a premium public multiple. Private kidney peers keep the current Strive mark from looking absurd, but they do not make it proven. Somatus disclosed a 2022 round above a $2.5 billion valuation, Monogram disclosed a large 2023 funding round and broad geographic reach, and Interwell disclosed very large covered-life and cost-under-management targets after its merger. Those facts show real investor appetite for kidney value-based care. They also come with serious comparability limits. The disclosed private marks are older, the business models mix provider networks, in-home delivery, or incumbent infrastructure differently, and none of those peer disclosures solve Strive's own missing revenue bridge. The comp set therefore supports a corridor of plausibility, not clean proof that the September 2025 mark was fair.[CV012, CV018, CV019, CV020, CV021, CV022]

8.3 The current mark is conditionally fair in a base case, but not yet proven

A scenario approach is more defensible than a synthetic revenue-multiple exercise because the missing input is not a decimal point; it is the entire monetization bridge. The bear case assumes that post-2026 kidney-policy tightening, downstream dialysis pricing pressure, and labor-heavy care delivery prevent Strive from converting scale into strong margins or durable renewals. In that world, the company starts to look more like an opaque care-operations asset than a premium tech-enabled platform, and the public-only valuation band falls well below the last round. The base case is narrower: Strive keeps growing, payer demand remains real, and private diligence shows the company does earn enough take rate and contribution margin for the current mark to be defensible. That can support a valuation band around the current price, but only conditionally. The bull case requires more than more members. It requires disclosed revenue quality, evidence that margins survive the 2026 reimbursement reset, and proof that Strive deserves a scarcity premium over public analogs that already disclose revenue and earnings. That framing leads to a practical recommendation rather than a heroic target. Strive is not an avoid from public evidence; the company has real strategic relevance, peer status, and a credible customer problem. It is also not a conviction buy at the disclosed September 2025 mark because the evidence quality on price support remains weak. The best public answer is research-more with medium confidence and a stretched-to-conditional-fair valuation stance. In plain language, the price may work, but management still has to prove why it works. Until revenue bridge, margin, renewal, and seniority data are shown, the current mark is bracketable, not bankable.[CV013, CV014, CV015, CV016, CV017, CV024]

8.4 The thesis survives only if private diligence closes a short list of decisive gaps

The decisive next step is not another narrative source; it is a disclosure package. Investors need management to show how medical spend converts into recognized revenue, gross profit, and cash generation by contract type. They also need the sensitivity of that economics stack to KCC resets, downstream dialysis pricing, and the relative weight of Medicare, Medicare Advantage, commercial, and Medicaid channels. Without that bridge, even a strategically strong company can be a poor investment at a rich entry price. The latest round's debt component raises the bar further, because the debt terms and any liquidation preference stack determine whether the headline mark maps cleanly to fresh equity upside. The decisive kill criteria are equally concrete. The thesis breaks quickly if management cannot show durable renewal rates, if current gross-margin logic depends on policy assumptions that already worsened in 2026, or if the company cannot separate differentiated economics from sheer medical-spend scale. A secondary break comes from capital structure: if debt covenants, liquidation preferences, or other senior claims absorb too much upside, the company can remain operationally interesting while still being an unattractive entry. That is why the final diligence asks are financial and contractual rather than philosophical. Strive has likely done enough to earn a deeper look. It has not yet done enough publicly to turn the September 2025 price into a clean yes.[CV037, CV039, CV040, CV042, CV044, CV045]

8.5 Exhibits